Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia

Annals of Hematology

Volumn 86, Issue 1, 2007, Pages 23-30

  Perifanis, Vassilios ^a   Vyzantiadis, Timoleon ^a   Tziomalos, Konstantinos ^a,b   Vakalopoulou, Sofia ^a   Garipidou, Vassilia ^a   Athanassiou Metaxa, Miranda ^a   Harsoulis, Faidon ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Beta thalassaemia major; Bisphosphonates; Insulin like growth factor 1; Osteocalcin; Osteoporosis; Osteoprotegerin; Zoledronic acid

Indexed keywords

ALFACALCIDOL; AMINO TERMINAL TELOPEPTIDE; CALCIUM CARBONATE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DEFERIPRONE; DEFEROXAMINE; ESTRADIOL; MEDROXYPROGESTERONE; OSTEOCALCIN; OSTEOPROTEGERIN; PREMELLE CYCLE 5; SOMATOMEDIN C; TESTOSTERONE ENANTATE; TESTOSVIRON; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUMBAR SPINE; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INSULIN-LIKE GROWTH FACTOR I; MALE; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDES; TREATMENT OUTCOME;

EID: 33846452110     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0180-7     Document Type: Article

References (59)

1. Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F et al (2003) Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48:824-828
2. Arrighi H, Khosla S, Melton LJ, Riggs BL, Bekker PJ, Dunstan CR (2000) The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. J Bone Miner Res 15(Suppl 1):S441
3. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J (1999) A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14:1557-1561
4. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
5. Cavallo L, Gurrado R, Gallo F, Zacchino C, De Mattia D, Tato L (1997) Growth deficiency in polytransfused beta-thalassaemia patients is not growth hormone dependent. Clin Endocrinol 46:701-706
6. Chrysis DC, Alexandrides TK, Koromantzou E, Georgopoulos N, Vassilakos P, Kiess W et al (2001) Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassaemia. Clin Endocrinol 54:253-259
7. Cornish J, Grey A, Callon KE, Naot D, Hill BL, Lin CQ et al (2004) Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem Biophys Res Commun 318:240-246
8. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 111:902-907
9. Erdtsieck RJ, Pols HA, Valk NK, van Ouwerkerk BM, Lamberts SW, Mulder P et al (1995) Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: A placebo controlled trial. Clin Endocrinol 43:557-565
10. Faulkner DL, Young C, Hutchins D, McCollam JS (1998) Patient noncompliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database. Menopause 5:226-229
11. Fazzalari NR, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM (2001) The ratio of messenger RNA levels of receptor activator of nuclear factor ΚB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015-1027
12. Fraher LJ, Watson PH, Kisiel M, Natale BV, Hodsman AB (2000) Measurement of circulating osteoprotegerin (OPG) in human sera: Inhibition of circulating OPG in osteoporotic patients treated with hPTH(1-34). J Bone Miner Res 15(Suppl 1):SU454
13. Geusens PP, Boonen S (2002) Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 58(Suppl 3):49-55
14. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J et al (1995) Abnormal bone metabolism in thalassaemia. In: Ando S et al (eds) Endocrine disorders in thalassaemia. Springer, Berlin Heidelberg New York, pp 39-46
15. Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C et al (2002) Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17:1961-1967
16. Herington AC, Werther GA, Mathews RN, Burger HG (1981) Studies on the possible mechanism for deficiency of non-suppressible insulin-like activity in thalassemia major. J Clin Endocrinol Metab 52:393-398
17. Hofbauer LC, Heufelder AE (2000) The role of osteoprotegerin and receptor activator of NF-ΚB ligand in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355-2363
18. Hofbauer LC, Schoppet M (2001) Serum measurement of osteoprotegerin. Clinical relevance and potential applications. Eur J Endocrinol 145:681-683
19. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-ΚB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-253
20. Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9-18
21. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A et al (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911-915
22. Kapitola J, Žák J, Lacinová Z, Justová V (2000) Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-1 levels in the rat. Physiol Res 49(Suppl 1):101-106
23. Kim YH, Kim GS, Jeong-Hwa B (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34:145-151
24. Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635
25. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
26. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570-575
27. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N (2002) Osteoporosis and beta-thalassemia major: Role of the IGF-I/ IGFBP-III axis. J Endocrinol Investig 25:338-344
28. Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
29. Low LC, Postel-Vinay MC, Kwan EY, Cheung PT (1998) Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with beta-thalassaemia major and the effect of GH treatment. Clin Endocrinol 48:641-646
30. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R (2003a) Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol 58:273-279
31. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A et al (2003b) Bone histomorphometry in children and adolescents with beta-thalassemia disease: Iron-associated focal osteomalacia. J Clin Endocrinol Metab 88:3966-3972
32. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567
33. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A et al (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644-649
34. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M et al (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle. J Bone Miner Res 19:722-727
35. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D et al The MK-677 Study Group (1999) Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res 14:1182-1188
36. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al MK-677/Alendronate Study Group (2001) Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86:1116-1125
37. Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT, Slootweg MC (1998) Growth hormone and bone. Endocr Rev 19:55-79
38. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A et al (2000) In vivo demonstration that parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871
39. Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402-408
40. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Engl J Med 346:653-661
41. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA (2004) IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol 60:491-499
42. Ruggiero L, De Sanctis V (1998) Multicentric study on prevalency of fractures in transfusion-dependent thalassemic patients. J Pediatr Endocrinol Metab 11:773-778
43. Seeman E, Tsalamandris C, Bass S, Pearce G (1995) Present and future of osteoporosis therapy. Bone 17(Suppl 2):23S-29S
44. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M et al (2003) Metabolic and endocrinologic complications in beta-thalassemia major: A multicenter study in Tehran. BMC Endocrine Disorders 3:1-6
45. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319
46. Soliman AT, El Banna N, Ansari BM (1998a) GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia. Eur J Endocrinol 138:394-400
47. Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM (1998b) Bone mineral density in prepubertal children with beta-thalassemia: Correlation with growth and hormonal data. Metabolism 47:541-548
48. Soliman AT, el Zalabany MM, Mazloum Y, Bedair SM, Ragab MS, Rogol AD et al (1999) Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) concentration in patients with beta thalassaemia and delayed growth. J Trop Pediatr 45:327-337
49. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162-3165
50. Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT (2003) Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 148:527-530
51. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C et al (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680-686
52. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R et al (2003) Therapy of osteoporosis in patients with Crohn's disease: A randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17:807-816
53. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A et al (2001) Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 112:36-41
54. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A et al (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123:730-737
55. Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127-139
56. Wonke B (1998) Bone disease in beta thalassaemia major. Br J Haematol 103:897-901
57. World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. W.H.O. Technical Report Series, 843
58. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A et al (1999) Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527
59. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL (2003) Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599-609